SETD4 and prostate carcinoma: Furthermore, RNA interference experiments suggest that downregulation of SETD4 may lead to a greater sensitivity to sorafenib in the HepG2 hepatocellular carcinoma (HCC) cell line, and have an impact on the survival of DU145 androgen‐independent prostate cancer cells [25, 26].